Related Experiment Video

Updated: May 22, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K

The prognosis of mild cognitive impairment: A systematic review and meta-analysis

Simone Salemme1,2, Flavia Lucia Lombardo3, Eleonora Lacorte3

  • 1Department of Biomedical Metabolic and Neural Sciences University of Modena and Reggio Emilia Modena Italy.

Alzheimer'S & Dementia (Amsterdam, Netherlands)
|March 13, 2025
PubMed
Abstract

Insights

Prognosis for mild cognitive impairment (MCI) differs by setting, with higher dementia conversion in clinical studies. Population studies show a significant 30% reversion rate, highlighting the need for better care pathways.

Area of Science:

  • Neurology
  • Gerontology
  • Public Health

Background:

  • Prognosis for mild cognitive impairment (MCI) remains incompletely understood, with significant variability in dementia conversion rates.
  • Reversion to normal cognition is an increasingly recognized outcome in MCI populations.

Purpose of the Study:

  • To synthesize current evidence on the prognosis of mild cognitive impairment (MCI).
  • To quantify conversion risk, stability, and reversion probabilities in different settings.
  • To identify factors influencing MCI prognosis.

Main Methods:

  • A meta-analysis of 89 studies with a minimum 3-year follow-up was conducted.
  • Studies utilized established criteria for MCI and dementia diagnosis.
  • Random-effects modeling was employed to assess prognosis outcomes; meta-regressions explored heterogeneity.

Main Results:

  • Overall MCI conversion risk was 41.5% in clinical settings and 27.0% in population-based studies.
  • Cognitive stability rates were approximately 50% in both settings.
  • Reversion rates varied significantly, with 8.7% in clinical studies and 28.2% in population studies.

Conclusions:

  • Dementia risk is higher and reversion less likely in clinical settings compared to population studies.
  • Cognitive stability is a common outcome for individuals with MCI.
  • Development of sustainable care pathways and further research in diverse settings are crucial.
Keywords:
Alzheimer's diseaseMCIbrain healthcognitive declineconversiondecentralizationdementiafunctional abilitymeta‐analysisprimary health carequality of carereversionsustainability

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.1K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

2.8K

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
40
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
409
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
88
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
82